Conflict of interest: Renu Gupta, MD: Executive Vice President and Chief Medical Officer, Insmed, Inc.; stock ownership, Insmed Inc.
Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung†
Version of Record online: 19 DEC 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 4, pages 580–586, April 2013
How to Cite
Chou, A. J., Gupta, R., Bell, M. D., Riewe, K. O., Meyers, P. A. and Gorlick, R. (2013), Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr. Blood Cancer, 60: 580–586. doi: 10.1002/pbc.24438
- Issue online: 13 FEB 2013
- Version of Record online: 19 DEC 2012
- Manuscript Accepted: 13 NOV 2012
- Manuscript Received: 6 JUN 2012
Additional Supporting Information may be found in the online version of this article.
|pbc_24438_sm_SuppFig1.tif||587K||Supplementary Figure 1|
|pbc_24438_sm_SuppTab1.doc||29K||Supplemental Table I. Serum concentrations of cisplatin during cycle 2, prior to dose #2 and 30 minutes after dose #2.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.